Patents Assigned to Flash Therapeutics
  • Patent number: 11371059
    Abstract: The present invention relates to retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest bound to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase, and at least one of said sequences of interest of the encapsidated non-viral RNAs comprises a part coding at least one epitope and/or at least one molecular structure specifically recognizing an epitope.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 28, 2022
    Assignee: FLASH THERAPEUTICS
    Inventors: Pascale Bouille, Christine Duthoit, Lucille Lamouroux
  • Patent number: 11124775
    Abstract: The present invention relates to a retroviral system for the transfer of non-viral RNA into target cells and more particularly a retroviral particle capable of delivering multiple RNAs. More particularly, it relates to retroviral particles comprising a protein derived from the Gag polyprotein an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest linked to an encapsidation sequence, each encapsidation sequence being recognised by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase.
    Type: Grant
    Filed: May 13, 2016
    Date of Patent: September 21, 2021
    Assignee: FLASH THERAPEUTICS
    Inventors: Pascale Bouille, Jean-Christophe Pages, Régis Gayon
  • Patent number: 10870865
    Abstract: The present invention relates to a retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest bound to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase, and at least one of said sequences of interest of the encapsidated non-viral RNAs comprises a part coding a nuclease.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: December 22, 2020
    Assignee: FLASH THERAPEUTICS
    Inventors: Pascale Bouille, Régis Gayon, Lucille Lamouroux, Alexandra Iche
  • Publication number: 20190203228
    Abstract: The present invention relates to retroviral particle comprising a protein derived from the Gag polyprotein, an envelope protein, optionally an integrase and at least two encapsidated non-viral RNAs, the encapsidated non-viral RNAs each comprising an RNA sequence of interest bound to an encapsidation sequence, each encapsidation sequence being recognized by a binding domain introduced into the protein derived from the Gag polyprotein and/or into the integrase, and at least one of said sequences of interest of the encapsidated non-viral RNAs comprises a part coding at least one epitope and/or at least one molecular structure specifically recognizing an epitope.
    Type: Application
    Filed: May 12, 2017
    Publication date: July 4, 2019
    Applicant: Flash Therapeutics
    Inventors: Pascale BOUILLE, Christine DUTHOIT, Lucille LAMOUROUX